Analysis of THC and CBD in Cannabis Commercial Oil: Preliminary Study
Keywords:
Δ9-THC and CBD, Cannabis oil, UPLC-PDAAbstract
Currently, cannabis oil is widely used without any control over production quality. It is therefore concerned that the unregulated number of active ingredients contained in the oil may affect the Thai public health system. To analyze the number of active ingredients in cannabis oil available on the market, this study was conducted. Δ9-THC and CBD quantification were analyzed with UPLC-PDA, linearity, LOD, and LOQ validity study. The method was then analyzed for Δ9-THC and CBD content in 60 cannabis oil samples. In this study, the method was linear in the concentration ranges of 0.50-5.00 μg/mL, with a correlation coefficient of >0.99 for all samples. The sensitivity was excellent, with LOD and LOQ of 0.10 μg/mL and 0.50 μg/mL of both. The accuracy and precision were very well with % recovery and % RSD of 95.85-106.44 and 1.68-6.54 for Δ9-THC, 88.58-102.21, and 0.67-5.97 for CBD, respectively. Δ9-THC and CBD content in cannabis oil was found. Each sample varies greatly, ranging from 0.00 -1,225.25 μg/mL for Δ9-THC, and 0.00-524.47 μg/mL for CBD. Therefore, the patient's use of cannabis oil with an unknown amount of the active ingredient may affect the health of the user.
References
Cannabis (online). [Cited 2023 JAN 9] Available:https://cannabis.fda.moph.go.th/
Clarke RC, Watson DP. Cannabis and natural cannabis medicine, in: M.A. ElSohly (Ed.), Marijuana and the Cannabinoids, Humana Press, NJ, 2007, pp. 1–16.
Solymosi K, Kofalvi A. Cannabis: A Treasure Trove or Pandora's Box? Mini Rev. Med. Chem. 2017, 17, 1223-1291.
Velasco G, Sánchez C, Guzman M. Towards the use of cannabinoids as antitumor agents. Nat.Rev. Cancer 2012, 12: 436-444.
Alexander SPH. Therapeutic potential of cannabis-related drugs. Prog. Neuro. Bio.Psych. 64, 2016: 157-166.
MacCallum CA, Russo EB. Practical considerations in medical cannabis administration and dosing. Eur.J. Intern. Med. 2018, 49: 12-19.
Yang Y, Lewis MM, Bello AM, Wasilewski E, Clarke HA, Kotra LP. Cannabis Sativa (Hemp) seeds, D9-tetrahydrocannabinol, and potential overdose, Cannabis Cannabinoid Res. 2.1, 2017, 274–281, DOI:http://dx.doi.org/ 10.1089/can.2017.0040.
U.S. Food and Drug Administration. FDA Approves First Drug Comprised of an Active Ingredient Derived from Marijuana to Treat Rare, Severe Forms of Epilepsy. FDA NEWS RELEASE.2018. [Cited 2023 JAN 9] Available:https://www.fda.gov/news-events/press-announcements/fda-approves-new-indication-drug-containing-active-ingredient-derived-cannabis-treat-seizures-rare
Commission E. Eur. Comm. Dir. Heal. Food Saf. rev. 2017, 0
Baumann K. Process Control Qual. 1997, 10, 75–112
Skoog DA, West DM, Holler FJ, Crouch S. Fundamentals of analytical chemistry (Nelson Education), 2013
Carr GP, Wahlich JC, Pharm J. Biomed. Anal, 1990, 8, 613–618
Commission E. Eur. Comm. Dir. Heal. Food Saf. rev. 2017, 0
Munawar AA, von Hörsten D, Wegener JK, Pawelzik E, Mörlein D. Eng Agric Environ Food, 2016,9(3): 208–215.
The use of medical marijuana extracts, infographic for doctors (online). [Cited 2023 JAN 9] Available:https://tmc.or.th/pdf/fact/guideline_cannabis_101062.pdf
Guidance on Cannabis for Medical Use; Department of Medical Services, Ministry of Public Health 4th revision (January 2023) (online). [Cited 2023 JAN 9] Available: https://mnfda.fda.moph.go.th/narcotic/wp-content/uploads/2021/04/Guidance-Updated-v-update-V.4260464.pdf
Srisubat A, Thanasitthichai S, Thaiyakul A, Konlaeaid S, Arunratanachot W, Imsuwansri T, et al. Outcomes of THC enriched in Advanced Staged Cancer Patients. Journal of Department of Medical Services 2020; 45(4):208-214.
Downloads
Published
Issue
Section
License
Copyright (c) 2024 KKU Research Journal (Graduate Studies)
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
